Abivax UC drug delivers strong remission in Phase 3, but safety signals spark caution
TL;DR Summary
Abivax’s ulcerative colitis therapy obefazimod showed high remission rates in a 580-patient Phase 3 maintenance trial, with about 51% remission at both 25 mg and 50 mg doses over 44 weeks versus 10.4% with placebo, suggesting strong efficacy. However, the company reported a few cancer cases among treated patients, raising safety concerns and sending shares lower after the results were disclosed.
- Abivax ulcerative colitis drug shows strong efficacy, but cases of cancer raise concerns statnews.com
- Biotech takeover target Abivax sinks over 43% as cancer cases cloud trial data for bowel disease drug CNBC
- Why This Biotech Plummeted Despite Its 'Best-Case' Study Investor's Business Daily
- Abivax Drops 32% On Cancer Signal: Jefferies Warns Of ‘Real’ Overhang But Retail Calls Selloff An ‘Overreaction’ Yahoo Finance
- Abivax Bowel-Disease Drug Hits Goals in Trial, But Shares Plunge on Safety Worries WSJ
Reading Insights
Total Reads
0
Unique Readers
4
Time Saved
2 min
vs 3 min read
Condensed
87%
476 → 61 words
Want the full story? Read the original article
Read on statnews.com